Kornimate/medical-research-clean huggingface dataset:
action observation therapy and mirror therapy in parkinson's disease

Conditions: Parkinson Disease; Tremor

Summary: small muscles of the hand are affected due to involuntary movements and slowing of voluntary movements seen in parkinson's disease. there is a loss of fine dexterity and coordination in the hand. it becomes difficult for patients to grasp and release of the objects. they become unable to perform daily activities such as buttoning up, holding keys, brushing teeth, holding forks, spoons and glasses, and writing. therefore, a certain part of the rehabilitation program should be devoted to upper extremity rehabilitation. the aim of this study was to compare the effects of action observation therapy and mirror therapy, which have been used in the literature for many years, on upper extremity functions and quality of life in individuals with parkinson's disease.


Eligibility criteria:
inclusion criteria: 1. 18 years and older, 2. diagnosed with idiopathic parkinson's disease, 3. parkinson's disease stage (patients with hoehn yahr≤3) 4. patients who can hear and follow verbal instructions. exclusion criteria: 1. patients who cannot cooperate, 2. patients with dementia or comorbidities affecting cognitive functions, 3. patients with serious comorbidities (such as decompensated heart failure, decompensated kidney failure) and significant disability (such as vision loss, hearing loss) affecting functionality, 4. patients with another disease (such as inflammatory diseases, polyneuropathy, brachial plexus lesion, loss of range of motion after trauma) affecting upper extremity functions. 5. patients diagnosed with secondary parkinson's disease 6. patients with acute neurological disease

Keywords: mirror therapy action observation therapy
potassium and sodium to control blood pressure in hypertensives

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases

Summary: to examine the role of dietary sodium reduction with and without potassium supplementation in controlling blood pressure in hypertensive men.

background: appropriately increased interest and concern about high blood pressure as a major public health problem coincided with the indication that the risks of hypertension-related morbidity and mortality could be reduced by reduction of blood pressure. consensus suggestions that individualized approaches be used in treating patients with mild hypertension stimulated further investigations of non-pharmacological methods. such investigations were also of considerable interest in relation to understanding the physiology of blood pressure control as well as the development of less costly non-drug therapies. interest was heightened by information suggesting that there might be distinctly harmful side effects related to antihypertensive drug therapy, particularly thiazide diuretics, in some settings. studies of non-drug therapies included dietary modifications primarily involving weight reduction and sodium restriction with increasing recent concern about other factors such as alcohol intake, dietary fat, calcium, magnesium, and potassium intake. design narrative: randomized, double-blind. one hundred forty-five subjects were randomized into a low sodium placebo group in which sodium intake was restricted to no more than 80 meq/day, 142 subjects into a potassium supplementation (96 meq/day) group whose sodium intake was also restricted to no more than 80 meq/day. after 12 weeks of intervention, antihypertensive drugs were withdrawn. follow-up of each participant was for at least two years. the primary endpoint was the proportion of subjects requiring antihypertensive medication at various points following randomization.

Eligibility criteria:
men, ages 45 to 68. subjects were hypertensive, were treated for at least 3.5 years with antihypertensive drugs and whose diastolic blood pressure was less than 90 mm hg.
haemodynamic effects of apelin agonists and antagonists in man in copd with raised pulmonary artery pressures

Conditions: COPD; Pulmonary Hypertension

Summary: the investigators are interested in studying how pulmonary hypertension occurs. a substance called 'apelin', that naturally occurs in the body has been shown to have an important role in heart disease. previous studies have shown that it can make blood vessels get wider, and help blood flow around the body and thus improve the way the heart and lungs work. the investigators are looking to recruit both healthy and copd pulmonary hypertension patients to study 3 types of apelin. the purpose of this study is to help the investigators understand how pulmonary hypertension occurs which may will help with the development of future treatments.

the purpose of this study: to investigate the physiological role of apelin in the cardiovascular system in patients with copd with raised pulmonary artery pressures. study aim and hypotheses: the primary objective is to test the above hypotheses using forearm blood flow and systemic infusions of apelin peptides. hypotheses: 1. apelin agonists are vasodilators in human resistance vessels and this effect will be altered in patients with pulmonary hypertension. 2. apelin peptides improve right ventricular and pulmonary haemodynamics in patients with elevated pulmonary artery pressures. study 1a - a validation dose study of 3 apelin agonists performed in healthy volunteers and copd patients with elevated pulmonary artery pressures. study 1b- a validation dose study of apelin receptor antagonist, in healthy volunteers and copd patients with elevated pulmonary artery pressures. study 2a - to define the haemodynamic response to apelin agonists in healthy volunteers and evaluate the response. study 2b - to investigate the haemodynamic response to 3 apelin agonists in copd patients with elevated pulmonary artery pressures.

Eligibility criteria:
inclusion criteria: * healthy volunteers * aged 18 to 70 years * non-smoker (\<1 cigarette per week) * if female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test copd patients with estimated pulmonary artery pressure (pap) on echo \>25mmhg * clinical diagnosis of copd as per standard criteria * between 18 and 70 years * if female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test exclusion criteria: * pre-existing: * systemic hypertension (sustained bp \>160/100mmhg) * ischaemic heart disease * primary valvular heart disease * significant left ventricular failure * active malignancy * renal disease (creatinine \>180 µmol/l) * neurological disease * diabetes mellitus * bmi \>35, bmi \<17 * pregnancy * use of vasoactive medication or nsaids/aspirin within 48 hours of study. * current involvement in other research studies, other than observational/non-interventional * known hiv

Keywords: copd apelin agonist antagonist
discomfort in upper airways due to intubation-a randomized controlled trial

Conditions: Postoperative Complications; Intubation; Difficult or Failed; Intubation Complication

Summary: few studies have compared different methods for optimalizing intubation conditions in general anesthesia. this randomized controlled trial will compare two different methods for intubation in general anesthesia in gastro- or gynecological procedures.

in general anesthesia, it is neccessary to secure the airways with an endotracheal tube. there is no international consensus on how intubation is most efficiently conducted. a cochrane review compared using muscular relaxing medication versus not using blocks for intubation. primary outcomes were intubation conditions and discomfort in upper airways. the authors concluded that research is limited, and that further research is needed. no studies have compared local anesthetic spray on the glottis and muscular relaxing medication in intubation, focusing on discomfort in upper airways. the null-hypothesis of this study is that there is no difference in upper airway discomfort when using local anesthetic spray or muscular relaxing medication. the study will have a randomized controlled design, randomizing patients undergoing gastro- or gynecological procedures in general anesthesia to receiving either rocuronium (muscle relaxing medication) intravenous, or lidocain spray on the glottis before intubation. the primary outcome is postoperativ hoarseness one hour after intubation.

Eligibility criteria:
inclusion criteria: * asa (american association of anesthesiologists classification system for physical status) i-iii * understand and can express themselves in norwegian * able to give informed consent to participate exclusion criteria: * cave lidocain and/or muscle relaxing medication * bmi above 40 * anticipated difficult intubation * need for ventricular tube * pathology or malformations in upper airways
controlled randomised trial of ferric carboxymaltose and oral iron to treat postpartum anemia

Conditions: Anemia, Iron-Deficiency; Puerperal Disorders; Depression, Postpartum

Summary: 200 patients with post partum anemia will be randomised to receive either intravenous iron (intervention group) or peroral iron (control group). the hypothesis is that intravenous iron supplementation is superior to standard peroral iron.

the study is a multi center phase 3 trial, comprising 3 medium sized obstetrical units in norway. the amount of iron given to the intervention group is calculated according to the modified ganzoni formula. the control group is given the standard regime of 200 mg ferro sulphate daily. in both groups, treatment start at inclusion, within 48 h of delivery. the sample size was based on power calculations: about 200 participants are required to detect a difference of 0.5 g/dl between the groups (with 80 % power). randomization is performed by use of opaque envelopes. an electronic crf is applied. laboratory analysis are provided by a recognized swedish biochemical laboratory. apart from hemoglobin and the common iron parameters, the serum concentration of soluble ferritin receptors will be analyzed, as well as hepcidin levels.

Eligibility criteria:
inclusion criteria: * woman within 48 h post partum * hemoglobin level equal or higher than 6.5 g/dl and equal or lower than 8.5 g/dl * able to read and understand the norwegian language * signed informed consent exclusion criteria: * anemia not attributable to iron deficiency * contraindications for any of the study drugs * treatment with drugs, dietary supplements or natural remedies containing iron * clinically significant condition which in the opinion of the investigator should disqualify the patient from the study * assessed as requiring blood transfusion(s)

Keywords: postpartum anemia, iron-deficiency
feasibility of at-home telehealth yoga for treating chronic pain

Conditions: Chronic Pain; Musculoskeletal Pain

Summary: this feasibility study will evaluate yoga as a treatment for chronic musculoskeletal pain. the experimental treatment is yoga delivered via a tablet computer to participants at home ("teleyoga"). first, the investigators will develop a suitable protocol for teleyoga. second, the investigators will demonstrate the feasibility of conducting a randomized controlled trial involving randomization to teleyoga or in-person yoga groups.

the first phase of the study is not randomized. in this phase, the first group of participants (n=10) will all participate in a tele-yoga class using an ipad loaned to them by the study. they will attend this treatment session from the comfort of their home or a location of their choice. yoga treatment will last 12 weeks. at the end of treatment, veterans will provide feedback by completing a satisfaction questionnaire to rate various aspects of the teleyoga (e.g. technical challenges, ability to perform yoga through the video-conferencing platform, problems that occurred, and recommendations to improve the class, etc). the teleyoga protocol will be modified on the basis of this feedback and will be tested on a second group of participants (n=10). the second phase of the study will involve randomization of a further group of participants (n=30) to either the teleyoga developed in phase one, or in-person yoga.

Eligibility criteria:
inclusion criteria: * veteran * medical clearance for participation by va primary care provider * diagnosis of musculoskeletal pain \> 6 months * minimum pain intensity of 4 at screening on 0-10 scale * any psychotropic treatments stable for at least 4 weeks before study * english literacy * wireless internet connection at home exclusion criteria: * current participation in another clinical trial * back surgery within the last 12 months * back pain related to a specific underlying cause, disease, or condition * baseline pain \ 9 on 0-10 scale * unstable, serious coexisting medical illness * unstable, serious coexisting mental illness * attended or practiced yoga ≥1 time in the past 12 months * active current suicidal plan or intent

Keywords: telehealth yoga
the effect of hypertrophic pyloric stenosis (hps) on sodium intake in childhood

Conditions: Healthy; Hypertrophic Pyloric Stenosis

Summary: the loss of sodium during infancy causes long term changes in sodium intake. human research shows that the loss of maternal sodium during pregnancy and neonatal after birth causes an increase sodium intake during childhood. a study that examined sodium intake among infants that were treated with diuretics during the post-natal period found changes in sodium intake compared to controls. in this study we will test sodium intake in young children who have suffered from vomiting due to hypertrophic pyloric stenosis during early infancy.


Eligibility criteria:
inclusion criteria: * children ages 7-13 years * status post hps in infancy exclusion criteria: * children with chronic diseases * hospitalization due to dehydration after hps hospitalization

Keywords: hypertrophic pyloric stenosis sodium intake healthy children with no chronic diseases status post hps
a study to evaluate the relative bioavailability and intra-subject variability of two lots of e5501 40 mg tablets administered twice as single oral doses to healthy subjects

Conditions: Idiopathic Thrombocytopenia Purpura

Summary: the purpose of this study is to evaluate the relative bioavailability (ba) of two lots of e5501 40 mg tablets administered twice as single oral doses to healthy subjects.

this is a randomized, open label, 4- way crossover, replicate design study to evaluate the bioavailability (ba) of e5501 new phase 3 formulation lot p97001zzb 40 mg tablet manufactured july, 2009 (treatment a ,reference drug) relative to lot p01010zza 40 mg tablet manufactured january, 2010 (treatment b, test drug) administered to 42 healthy male and female subjects.

Eligibility criteria:
inclusion criteria: * normal healthy adult male or female subjects age greater than or equal to 18 years and less than or equal to 55 years old. * body mass index greater than or equal to 18 kg/m2 and less than or equal to 32 kg/m2 at the time of screening. * platelet count between 120x109/l and 250x109/l. * women of childbearing potential must agree to use a double barrier method of contraception during the randomization phase of the study. exclusion criteria: * evidence of clinically significant cardiovascular, hepatic, gastrointestinal, renal, respiratory, endocrine, hematologic, neurologic, or psychiatric disease or abnormalities or a known history of any gastrointestinal surgery that could impact the pharmacokinetics (pk)of the study drug. * agents associated with thrombotic events (including oral contraceptives) must be discontinued within 30 days of the first study drug administration. * evidence of organ dysfunction or any clinically significant deviation from normal in their medical history, e.g., history of splenectomy. * history of venous or arterial thrombotic disease or other hypercoaguable state. * hemoglobin level less than 11.5 g/dl for females and 13.5g /dl for males
long-term monitoring of growth and development of pediatric patients previously treated with everolimus

Conditions: Growth and Development

Summary: the primary objective of crad001m2305 was to report the long-term effects of everolimus treatment on height, weight and sexual development (using tanner stages) in children and adolescents with tuberous sclerosis complex (tsc)-associated with subependymal giant cell astrocytoma (sega). the study monitored the growth and development of pediatric patients with tsc-associated sega, previously enrolled in crad001m2301 (nct00789828) until they reach tanner stage v, or until age 16 for females or 17 for males whichever occurred first.

crad001m2305 was a prospective, multi-center phase iiib/iv study. this study investigated if the physical and sexual development of pediatric patients was affected by previous or ongoing treatment with everolimus. the study monitored the growth and development of pediatric patients with tsc-associated sega, previously enrolled in crad001m2301(nct00789828) until they reached tanner stage v, or until age 16 for females or 17 for males whichever occurred first. continued treatment with everolimus was at investigator discretion and was not required for participation in crad001m2305. growth (height, weight), and sexual development (tanner stages, sex hormone levels, age at menarche, thelarche (females) and adrenarche (males)), and brain development (assessed by tand checklist, dates of brain mri) of patients participating in this long-term follow-up study was followed at annual visits to the site until patients achieve tanner stage v or age 16 (females), age 17 (males) whichever occurred first. adverse events, concomitant medication, appearance of menarche, were monitored and data collected every 3 months ("3-monthly"). unless clinically indicated these 3-monthly visits were performed per telephone.

Eligibility criteria:
inclusion criteria: * pediatric female patients who were on study treatment in study \[crad001m2301\] within the past 6 months and have not reached tanner stage v or age 16 at the time of completion of \[crad001m2301\] or * pediatric male patients who were on study treatment in study \[crad001m2301\] within the past 6 months and have not reached tanner stage v or age 17 at the time of completion of \[crad001m2301\] * written informed consent according to local guidelines exclusion criteria: * pediatric female patients who were on study treatment in crad001m2301 and have not reached tanner stage v but are within 3 month of turning age 16 or * pediatric male patients who were on study treatment in crad001m2301 and have not reached tanner stage v but are within 3 months of turning age 17 * any patient who was pregnant prior to start of crad001m2305

Keywords: tsc-associated sega, height, weight, tanner stage, growth development, everolimus, rad001
fragmented sleep, pain, and biomechanics

Conditions: Pain; Healthy; Sleep Disturbance

Summary: this interventional study aims to test the effects of sleep disruption on pain sensitivity and biomechanics in healthy individuals during experimental knee and shoulder pain. the main question the study aims to answer is: 1) does sleep fragmentation increase experimental knee and shoulder pain and what are the underlying mechanisms? participants will receive two injections a) hypertonic saline (painful) in the knee and b) hypertonic saline (painful) in the upper arm.

this study will include healthy participants for one baseline session and one follow-up session separated by three nights of experimental sleep disruption. the sleep fragmentation will involve three forced awakenings per night for three consecutive nights between sessions. these awakenings will be planned at 00:00, 02:30, and 05:00. in each session, the participant will answer questionnaires and have their pain sensitivity assessed using cuff-pressure algometry. following this, they will first receive a painful saline injection into the infrapatellar fat pad of the knee. after a washout period, they will receive another painful saline injection into the deltoid muscle of the shoulder. for both injections, the pain will be rated on an nrs scale (0 representing 'no pain' and 10 representing 'worst pain imaginable') every 30 seconds, and the distribution will be marked on a body chart.

Eligibility criteria:
inclusion criteria: * healthy men and women aged 18-45 years * must have a smartphone available during the experiment exclusion criteria: * pregnancy * drug addiction, defined as the use of cannabis, opioids, or other drugs * previous or current neurologic or musculoskeletal illnesses * current pain * lack of ability to cooperate
esophageal balloon guided weaning of the morbidly obese patient

Conditions: Morbid Obesity

Summary: this is a study to evaluate whether peep adjusted by use of an esophageal balloon to overcome negative transpulmonary pressure; or adjusted by use of "cstat" to achieve the best effective static compliance will have any effect on outcomes with respect to ventilator weaning in tracheotomized morbidly obese patients (bmi \>=40) with at least one failed prior weaning attempt.

tracheotomized morbidly obese patients (bmi \>= 40) who had failed an initial attempt at ventilator weaning (defined in the investigators study as ventilator dependent) were randomly assigned to one of two methods for setting positive end expiratory pressure (peep). patients randomized to the esophageal balloon arm (eso group) had their peep adjusted to overcome negative transpulmonary pressure and maintain a positive transpulmonary pressure (ptp) of 0 to 10 cm h20 - targeting as close to zero as possible. patients randomized to the static effective compliance arm (cstat group) had their peep adjusted to achieve the best static effective compliance as automatically calculated and displayed on the graphic interphase of the hamilton g5 or galileo ventilator. for this group, the peep was adjusted in increments of 3 cm h20 until there was a less than 5% observed improvement in the static effective compliance. the peep with the best cstat was chosen. at the end of the intervention period, this intervention cohort (termed "peep intervention cohort") will be compared to a group of historical controls to compare the efficiency of a peep-based weaning protocol to traditional weaning methods. the investigators hypothesized that peep levels titrated by use of an esophageal balloon to maintain a positive transpulmonary pressure between 0 to 10 cm h20, would lead to improved outcomes with respect to ventilator weaning in this subset of patients.

Eligibility criteria:
inclusion criteria: * morbidly obese patients with bmi of 40 or greater * ventilator dependent patients (defined as at least one prior failure at weaning) * tracheotomized * no active underlying lung disease that would preclude ventilator weaning * stable hemodynamics * patient/ family able to give consent * no naso-facial abnormalities that would interfere with placement of an esophageal balloon * fio2 \<= 60% * patient able to tolerate pressure support ventilation exclusion criteria: * lack of consent * patient deemed not weanable from mechanical ventilation as per the clinical judgement of the pulmonary physician * significant lung, heart or neuromuscular disease that would interfere with or preclude ventilator weaning, including an active ongoing lung infection. * contraindications to placement of an esophageal pressure monitoring device - such as ulcerations, tumors, diverticulitis, uncontrolled bleeding varices, sinusitis, epistaxis or recent nasopharyngeal surgery

Keywords: transpulmonary pressure esophageal balloon esophageal pressure monitoring device cstat static effective compliance ventilator weaning morbidly obese ventilator dependent tracheotomized patients